Physician profile
Daniel Ott
NPI 1083621205
$801.91
in general payments reported to CMS, 2019-2025
16 companies · $30.19 in 2025
The $30.19 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $74.60 · 2021: $166 · 2022: $72.07 · 2023: $13.72 · 2024: $43.87 · 2025: $30.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $303.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.60 | 2020-2022 | |
| Glaxosmithkline, LLC. | $56.53 | 2019-2021 | |
| Adlon Therapeutics L.P. | $50.45 | 2019-2021 | |
| Sanofi Pasteur INC. | $40.15 | 2019-2023 | |
| Corium, LLC | $38.59 | 2022 | |
| Neos Therapeutics, Lp | $33.18 | 2019 | |
| Novo Nordisk INC | $30.19 | 2025 | Wegovy |
| Inari Medical, INC. | $26.09 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alk-Abello, INC | $17.78 | 2024 | Ragwitek, Odactra, Grastek |
| Phadia US INC. | $16.03 | 2021 | |
| Shire North American Group INC | $13.60 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.99 | 2019 | |
| Pfizer INC. | $11.96 | 2019 | |
| Incyte Corporation | $11.17 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.